Evidence map›Paper›PMID 40760870›Full record

ArticleInternal medicine journal2025

Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia.

Georgia McCaughan, Hayley Beer, Christian Bryant, P Joy Ho, Tracy King, Cindy Lee, Peter Mollee, H Miles Prince, Andrew Spencer, Dipti Talaulikar and 5 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Patient preferences for treatment‑free intervals in multiple myeloma: mixed‑methods insights on monitoring trade‑offs and supportive care improvements.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Georgia McCaughanDepartment of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
Hayley BeerClinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Christian BryantInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
P Joy HoInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.ORCID 0000-0002-2811-8671
Tracy KingInstitute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Cindy LeeDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Peter MolleeHaematology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
H Miles PrinceClinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Andrew SpencerAustralian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
Dipti TalaulikarDepartment of Diagnostic Genomics, Canberra Health Services, Canberra, Australian Capital Territory, Australia.ORCID 0000-0001-6766-8345
Kate VandykeMyeloma Research Laboratory, School of Biomedicine, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia.
Nicholas WeberRoyal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Angelina YongDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Simon HarrisonClinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Hang QuachFaculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The survival of newly diagnosed patients with multiple myeloma has improved significantly over the past 20 years with significant therapeutic advances. Despite this, high-dose chemotherapy followed by autologous stem cell transplantation remains the standard of care in newly diagnosed patients who are considered transplant eligible. Here, we summarise the recommendations of the Medical and Scientific Advisory Group of Myeloma Australia for patients considered suitable for high-dose chemotherapy and autologous stem cell transplantation as part of the initial therapy.

Indexed as

Advisory CommitteesDisease ManagementHematopoietic Stem Cell TransplantationMultiple MyelomaStem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsAustraliaHumansTransplantation, Autologousautologous stem cell transplantationinductionmaintenancemultiple myelomanewly diagnosed

Identifiers

PMID40760870
PMCPMC12515471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.